Journal of Cancer Research and Practice最新文献_第2页

Recurrent diffuse large B-Cell lymphoma with the initial manifestation of retinal involvement 复发性弥漫性大b细胞淋巴瘤，初始表现为累及视网膜

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00034

Jen-Tsun Lin, Wan-Ting Yeh

引用次数: 0

Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: A single-center experience in Taiwan focusing on efficacy 达拉图单抗-来那度胺-地塞米松治疗复发/难治性多发性骨髓瘤患者的真实证据:台湾单中心疗效研究

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00032

Ling-Jung Chiu, C. Kuo, M. Ma, Chun- Liao, Hung-Lin Liu, M. Wang

{"title":"Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: A single-center experience in Taiwan focusing on efficacy","authors":"Ling-Jung Chiu, C. Kuo, M. Ma, Chun- Liao, Hung-Lin Liu, M. Wang","doi":"10.4103/ejcrp.ejcrp-d-22-00032","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-22-00032","url":null,"abstract":"Background: Daratumumab (DARA) introduced in the multiple myeloma (MM) treatment strategy, producing a direct antitumor activity and immunomodulatory effects in phase I-II trial GEN501. In the POLLUX trial, the combination of DARA with lenalidomide and dexamethasone (DRd) reported impressive response rates. In Taiwan, the Dara-based regimen was supported by National Health Insurance recently, but there were no real-world data in Taiwan. Materials and Methods: We described a heavily pretreated group of 31 patients with MM who had received one or more lines of therapy to receive DRd therapy after Taiwan Food and Drug Administration approval. The primary end point was progression-free survival (PFS). Results: After a median follow-up of 22.87 (95% confidence interval [CI]: 16–29.73) months, the median time to first response was 59 days (95% CI: 24.8–81.6). Median PFS was 24.082 months (95% CI: 14–33) in patients who received DRd therapy. Twelve-month PFS showed 80.7% in the DRd group. Patients who achieved at least very good partial response (VGPR) had longer median PFS (39.8 months) than those who achieved partial response (7.35 months). The complete response rate and VGPR were 35.5% and 29%, respectively. About 22.6% of patients had a partial response. The average treatment duration was 11.48 ± 7 months. Patient experienced biological relapse at 5.88 months after discontinuing DRd treatment. Conclusion: After DRd treatment for 11.48 months, most of the patients showed biological relapse at 5.88 months, suggesting the good efficacy; however, the need of a longer maintenance treatment of DARA. The median PFS in real-world setting was consistent with the POLLUX trial regardless of more patients with high cytogenetic risks. Patient who could achieve deep response above VGPR had better PFS than those who did not.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"19 - 23"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47826251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy 贝伐单抗预处理联合依托泊苷和顺铂方案对全脑放疗难治的人表皮生长因子受体2阳性乳腺癌症脑转移的抗肿瘤疗效

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-23-00001

T. Chen, Ching-Hung Lin, D. Yeh, L. Tseng, K. Rau, Bang-Bin Chen, T. Chao, Shu-Min Huang, D. Chang, I. Chen, A. Cheng, Yen-Shen Lu

{"title":"Anti-tumor efficacy of a bevacizumab preconditioning followed by etoposide and cisplatin regimen in human epidermal growth factor receptor-2-positive breast cancer brain metastasis refractory to whole brain radiotherapy","authors":"T. Chen, Ching-Hung Lin, D. Yeh, L. Tseng, K. Rau, Bang-Bin Chen, T. Chao, Shu-Min Huang, D. Chang, I. Chen, A. Cheng, Yen-Shen Lu","doi":"10.4103/ejcrp.ejcrp-d-23-00001","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-23-00001","url":null,"abstract":"Background: For human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC), treating brain metastasis (BM) remains challenging. We have previously demonstrated that administering bevacizumab 1 day before etoposide and cisplatin (BEEP) can significantly improve antitumor efficacy in cases of breast cancer with BM. Herein, we report the antimetastatic brain tumor efficacy of BEEP in an HER2-positive subpopulation. Materials and Methods: Thirty-five MBC patients with BM were enrolled from January 2011 to January 2013. BEEP was given in 21 day cycles: bevacizumab 15 mg/kg on day 1, etoposide 70 mg/m2/day from days 2 to 4, and cisplatin 70 mg/m2 on day 2. The primary endpoint was composite central nervous system (CNS) volumetric objective response rate (ORR). Anti-HER2 treatments were not permitted during the clinical trial. Results: A total of 23 patients were HER2-positive, 9 ER-positive, and 14 ER-negative. All had been exposed to trastuzumab; 11 (47.8%) had received lapatinib treatment, and 6 (26.1%) of them had received both lapatinib and capecitabine treatment. Of these, 16 patients (69.6%, 95% confidence interval [CI] 47.1–86.8) achieved CNS-ORR, including 7 (30.4%) with ≥80% and 9 (39.1%) with 50%–80% CNS volumetric reduction. A further 5 patients (21.7%) had 20%–50% CNS volumetric reduction. Median CNS-specific progression-free survival and overall survival were 7.4 (95% CI 5.8–9.0) and 11.8 (95% CI 8.7–14.9) months, respectively. Toxicities were tolerated with granulocyte-colony stimulating factor support. Conclusion: The BEEP regimen had a significant antitumor effect in cases of BM of HER2-positive breast cancer that progressed following whole brain radiotherapy.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"11 - 18"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44048486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset 依维莫司联合依西美坦治疗难治性激素受体阳性、人表皮生长因子受体2阴性的绝经后晚期乳腺癌的安全性和有效性:来自EVEREXES台湾亚群的分析

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-23-00008

Chiun-Sheng Huang, Yuan-Ching Chang, Kun-Ming Rau, Dar-Ren Chen, Tsu-Yi Chao, Ming-Feng Hou

{"title":"Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset","authors":"Chiun-Sheng Huang, Yuan-Ching Chang, Kun-Ming Rau, Dar-Ren Chen, Tsu-Yi Chao, Ming-Feng Hou","doi":"10.4103/ejcrp.ejcrp-d-23-00008","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-23-00008","url":null,"abstract":"Background: This phase IIIb, open-label study enrolled patients from nine Asian and Middle Eastern countries to evaluate the safety and efficacy of the combination therapy in underrepresented patient populations from the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2). Here, we report the Taiwanese subset data. Materials and Methods: The primary objective was to evaluate the safety and tolerability of everolimus and exemestane (EVE + EXE); the secondary endpoints included progression-free survival (PFS), response rates, and clinical benefit rate. Postmenopausal patients who had metastatic, recurrent, or locally advanced hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) refractory to nonsteroidal aromatase inhibitor (NSAI) and had received EVE + EXE were recruited. Results: From March 2013 to October 2014, 235 postmenopausal women were enrolled in EVEREXES. Taiwanese patients (n = 22) had similar baseline characteristics compared with BOLERO-2 cohort; most (17/22) had discontinued due to disease progression. Only two patients dropped out due to unacceptable adverse events (AEs) despite worse stomatitis (any 77.3%; grade 3/4, 18.2%). Other common AEs included pneumonitis (45.5%), rash (27.3%), and hyperglycemia (9.1%). PFS and safety in EVEREXES compared favorably with BOLERO-2, especially among Taiwanese patients (median: 49 weeks; 95% confidence interval = 19.3–82.0). Conclusion: Although EVEREXES had a small Taiwanese population, the encouraging outcomes compared with BOLERO-2 showed that EVE + EXE is safe for Taiwanese patients with HR+ HER2− ABC who progressed on NSAIs. Large-scale verification is warranted.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135602426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of wnt ligand secretion mediator signaling in cancer development wnt配体分泌介导信号在癌症发展中的作用

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00029

Kai-Ting Chuang, Li-Ting Wang, S. Hsu

{"title":"Role of wnt ligand secretion mediator signaling in cancer development","authors":"Kai-Ting Chuang, Li-Ting Wang, S. Hsu","doi":"10.4103/ejcrp.ejcrp-d-22-00029","DOIUrl":"https://doi.org/10.4103/ejcrp.ejcrp-d-22-00029","url":null,"abstract":"Objective: The Wnt signaling pathway is among the crucial cascades that regulate development and homeostasis of tissue. Data Sources: Further, it is closely associated with different types of cancer, which includes glioma, breast, colorectal, lung, and prostate cancer, and hepatocellular carcinoma (HCC). The deviant activation or inhibition of Wnt signaling regulates cancer progression, thereby exerting oncogenic or tumorsuppressive effects that control the invasion, metastasis, and metabolism of cancer cell. Study Selection: In the Wnt secretory pathway, lipidmodified Wnt molecules interact with Wnt ligand secretion mediator (WLS), a Wnt cargo receptor. Moreover, they are directed to the plasma membrane and then secreted. Results: Loss of WLS function leads to the accumulation of Wnt in the endoplasmic reticulum (ER), leading to retrograde Golgi–ER transport and ER stress associated with the pathogenesis of several conditions, including early embryonic death, and developmental defects related to lymphopoiesis, neurogenesis, and osteogenesis in adults. Although there is substantial evidence, the regulatory mechanisms through which WLS controls cellular functions are not fully elucidated. Conclusion: Therefore, the current study aimed to identify the underlying mechanism of the effects of WLS on the development of human diseases.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"10 1","pages":"1 - 10"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70714628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary pancreatic hepatoid carcinoma: A case report and literature review 原发性胰样肝癌1例报告并文献复习

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00037

Hsiang-Fong Kao, Tyng-Wei Yang

引用次数: 0

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/2311-3006.371526

C. Chiu, Jhe-Cyuan Guo

引用次数: 1

Idiopathic multicentric castleman disease following SARS-CoV-2 vaccination SARS-CoV-2疫苗接种后的特发性多中心castleman病

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00035

Pang-Yu Lai, Chien-Yu Ker, Hung-Wei Liu, Yu-Chieh Su

引用次数: 0

Frontline autologous stem cell transplantation in POEMS syndrome with pulmonary arterial hypertension 前沿自体干细胞移植治疗POEMS综合征合并肺动脉高压

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-22-00022

Polev Li, Hsin-Chen Lin

引用次数: 0

Middle ear metastases as the initial presentation of breast cancer progression 中耳转移是乳腺癌进展的初始表现

Journal of Cancer Research and Practice Pub Date : 2023-01-01 DOI: 10.4103/ejcrp.ejcrp-d-23-00009

Wei-Pang Chung, Tzu-Chien Lin, Ya-Chun Hsu, Hui-Wen Chen

引用次数: 0